The publication in a peer-reviewed journal and encouraging OS data (17.3 months in refractory HNSCC) could drive near-term speculative buying. However, the stock has historically reversed gains within 5 days on similar news. Monitor for partnership announcements or financing updates; the SYN-004 trial is stalled pending funding, which may cap upside.
TOVX drugs
TOVX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 11 $0.3070entry
- T+1 · 5mo ago −1.04%α −1.58% · $0.3038
- T+5 · 5mo ago −12.05%α −12.49% · $0.2700
- T+20 · 4mo ago −23.62%α −25.51% · $0.2345
- T+60 · 2mo ago −17.59%α −21.99% · $0.2530
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theriva Biologics announced publication of Phase 1 trial results for VCN-01 in immunotherapy-refractory HNSCC in Clinical Cancer Research. The data showed median overall survival of up to 17.3 months in the high-dose sequential arm, with translational evidence of immune resensitization.
Key Facts
- Phase 1 trial results published in Clinical Cancer Research for VCN-01 + durvalumab in immunotherapy-refractory metastatic HNSCC
- Median overall survival: 10.3 months (Arm I LD), 15.5 months (Arm II LD), 17.3 months (Arm II HD)
- Median progression-free survival: 1.6 months (Arm I LD), 3.7 months (Arm II LD), 2.1 months (Arm II HD)
- Biomarker data showed increased PD-L1+ T-cells, CD8 upregulation, and reduced Treg markers consistent with immune reactivation
- 20 patients enrolled across three arms; no new safety signals highlighted
- SYN-004 (ribaxamase) HCT trial has completed 2 of 3 cohorts, with third cohort dependent on additional funding
Financial Impact
No financial data provided; pre-revenue clinical-stage company with $11M market cap. Positive Phase 1 data may support partnering or financing but no near-term revenue.
Risk Factors
- Micro-cap biotech with $11M market cap, high volatility and liquidity risk
- Phase 1 data is early; larger randomized trials needed for regulatory approval
- SYN-004 HCT trial requires additional funding to complete third cohort
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310376 |
Track record
11 reports on TOVX
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
- Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
- Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
- Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Viewing Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
- Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
- Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers